Solid compositions of cocrystals of cannabinoids

A cocrystal of a cannabinoid selected from (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol, (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol, 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol, 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol and 2-((1R,6R)-3-methyl-6-(prop-1-en-2-yl) cyclohex-2-enyl)-5-propylbenzene-1,3-diol and a zwitterion conformer, which is a cocrystal selected from the group consisting of:

• (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol and L-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 5.1, 11.5 and 20.5±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol and D-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 5.1, 11.4 and 20.6±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol and L-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 5.1, 18.7 and 20.5±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol and D-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 5.1, 16.1 and 20.4±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol and betaine characterized by having an X-ray diffractogram that comprises characteristic peaks at 6.3, 7.1 and 9.0±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol and L-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 4.2, 5.6 and 9.0±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol and L-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 4.7, 10.9 and 12.5±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol and D-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 4.7, 10.9 and 12.5±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol and D-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 5.1, 10.2 and 16.1±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol and betaine characterized by having an X-ray diffractogram that comprises characteristic peaks at 7.8, 15.8 and 23.8±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol and L-carnitine characterized by having an X-ray diffractogram that comprises characteristic peaks at 7.0, 14.1 and 19.8±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• 2-((1R,6R)-3-methyl-6-(prop-1-en-2-yl) cyclohex-2-enyl)-5-propylbenzene-1,3-diol and L-proline characterized by having an X-ray diffractogram that comprises characteristic peaks at 6.1, 9.8 and 12.0±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å;
• and
• 2-((1R,6R)-3-methyl-6-(prop-1-en-2-yl) cyclohex-2-enyl)-5-propylbenzene-1,3-diol and L-carnitine characterized by having an X-ray diffractogram that comprises characteristic peaks at 6.9, 10.6 and 11.1±0.3 degrees 2 theta at a Cu-Kα radiation, λ=1.5406 Å.